1 **Synthetic biology meets proteomics: Construction of *à la carte* QconCATs for absolute protein quantification**

2

3 James Johnson[1], Victoria M Harman[2], Catarina Franco[2], Nicola Rockliffe[1], Yaqi Sun[3], Lu-Ning Liu[3], Ayako

4 Takemori[4], Nobuaki Takemori[4] & Robert J. Beynon[2,¶]

5

6

7 [1]GeneMill, Institute of Systems Molecular and Integrative Biology, University of Liverpool, Crown Street,

8 Liverpool, L69 7ZB, UK

9

10

11 [2]Centre for Proteome Research, **Institute of Systems and Integrative Biology**, University of Liverpool, Crown

12 Street, L697ZB, Liverpool, United Kingdom

13

14 [3]Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Crown Street, L697ZB,

15 Liverpool, United Kingdom

16

17 [4]Division of Analytical Bio-Medicine, Advanced Research Support Center, Ehime University, Shitsukawa,

18 Toon, Ehime, Japan

19

20

21

22

23

24

25 ¶Corresponding author: Robert J. Beynon (r.beynon@liverpool.ac.uk)

26

27 Keywords: synthetic biology, QconCAT, quantitative proteomics, loop assembly,

28

29 Short title: *À la carte* QconCATs

30

ABSTRACT

We report a new approach to the assembly and construction of QconCATs, quantitative concatamers for proteomic applications that yield stoichiometric quantities of sets of stable isotope-labelled internal standards. The new approach is based on synthetic biology precepts of biobricks, making use of loop assembly to construct larger entities from individual biobricks. It offers a major gain in flexibility of QconCAT implementation and enables rapid and efficient editability that permits, for example, substitution of one peptide for another. The basic building block (a Qbrick) is a segment of DNA that encodes two or more quantification peptides for a single protein, readily held in a repository as a library resource. These Qbricks are then assembled in a one tube ligation reaction that enforces the order of assembly, to yield short QconCATs that are useable for small quantification products. However, the DNA context of the short also allows a second cycle of assembly such that five different short QconCATs can be assembled into a longer QconCAT in a second, single tube ligation. From a library of Qbricks, a bespoke QconCAT can be assembled quickly and efficiently in a form suitable for expression and labelling i*n vivo* or *in vitro*. We refer to this approach as the ALACAT strategy as it permits *à la carte* design of quantification standards.

INTRODUCTION

Absolute quantification of proteins by mass spectrometry is typically based on the use of accurately quantified stable isotope labelled internal standards, usually peptides, as surrogates for the protein quantification. There are many ways to generate these labelled peptides, including direct chemical synthesis (AQUA peptides, [1, 2] or are derived from full length labelled proteins (PSAQ, [3–5] or shorter epitopic fragments (PrEST, [6, 7]). An additional approach is the use of QconCAT technology [4, 8, 9]. QconCATs are multiplexed protein standards for proteomics, products of artificial genes designed to encode concatamers of peptides, wherein each peptide or more commonly, a pair of peptides, is chosen to act as mass spectrometric standard(s) for absolute quantification of multiple peptides. The initial publications on QconCATs [10–12] have received over 1,000 citations and the methodology is well known and embedded in the community. At a typical size of about 60-70 kDa, a QconCAT encodes approximately 50 tryptic peptides, permitting the quantification of around 25 proteins at a ratio of two peptides per protein. The genes are then expressed as recombinant proteins in bacteria grown in the presence of SIL amino acids, usually lysine and arginine, ensuring a single labelling position for every standard tryptic peptide. Because the genes are designed *de novo*, it is feasible to introduce additional features, such as purification tags, sacrificial peptides to protect the QconCAT from exoproteolysis and peptide sequences, common to each QconCAT as a quantification standard, permitting absolute quantification of each standard within the proteomics workflow – in effect, an 'internally standardised standard'. We have demonstrated that the QconCAT approach can be used successfully in large scale proteome quantification studies and have reported the absolute

65　　quantification of approx. 1,800 proteins in the *Saccharomyces cerevisiae* proteome [13], by far the largest

66　　absolute quantification study conducted to date. Because each peptide derived by complete excision from a

67　　QconCAT are present in equal quantities, QconCATs also have utility in determination of subunit stoichiometry of

68　　multiprotein complexes, such as the proteinaceous bacterial metabolosomes for propanediol degradation in

69　　*Salmonella* [14].

70

71　　Although QconCATs have been widely adopted, their broader deployment can be challenging. First, QconCAT

72　　expression requires skills in molecular biology and facilities for bacterial expression of heterologous proteins. We

73　　have addressed this in part through the introduction of cell-free synthesis of QconCATs, which brings added

74　　advantages of concurrent, single tube synthesis that we have extended to over 100 QconCATs simultaneously, a

75　　strategy we have dubbed MEERCAT [15, 16]. Secondly, QconCATs cover a set of target proteins based on the

76　　needs of one research group, which may not always match the requirements of subsequent research groups.

77　　Thirdly, the choice of peptides is often obliged to be made without knowledge of the performance of these

78　　peptides in absolute quantification. Lastly, editing of any QconCAT, for example, the removal or addition of a

79　　single protein, has required complete resynthesis and expression of the gene.

80

81　　To overcome these complications, we now introduce the concept of 'ALACATS' - *'à la carte'* QconCATs, the term

82　　reflecting the ability to design a QconCAT of any length that encodes peptides for a user-specified set of target

83　　proteins. ALACATS are assembled from 'Qbricks', oligonucleotides that encode (typically) two quantotypic

84　　peptides for a single target protein, together with short flanking peptides to recapitulate the correct primary

85　　sequence context, and thus normalise digestion rates. Each Qbrick (one for each target protein in the proteome)

86　　is a discrete entity, a double stranded DNA construct that can be readily synthesised, stored, catalogued and

87　　accessed to enable the synthesis of an ALACAT to order. These are the fundamental building blocks in the ALACAT

88　　workflow.

89

90　　**RESULTS**

91　　**Design, synthesis and assembly of Qbricks**

92　　A Qbrick ('quantification brick', a type of biobrick [17]) is defined as a short, double stranded oligonucleotide that

93　　encodes two Qpeptides that are quantotypic for a single protein and is thus the smallest building block (Figure 1).

94　　The Qbrick also encodes interspersed peptide sequences that recapitulate the primary sequence context of the

95　　two peptides, thus equalising digestion rates of standard and analyte. Each Qbrick has asymmetric overhangs at

96　　each end, creating sticky ended DNA molecules that permit assembly by a strategy called 'Loop Assembly', driven

97　　by sequential use of two Type IIS restriction endonucleases [18]. Different unique overhang sequences (A, B, C,

98　　D, E and F) flank the Qbricks. Five Qbricks are assembled in a single reaction – the 'odd' cycle [18]. The annealing

ALACATs: à la carte QconCATs　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　3

99 during assembly maintains the reading frame through the QconCAT, adding two amino acids to the interspersed

100 linker with little or no effect on the peptides generated from the QconCAT (Figure 1a). These *short QconCATs*,

101 assemblies of five Qbricks that encode 10 peptides, are perfectly useable when expressed as a five-target protein

102 standard suitable for small, focused studies. A short QconCAT, containing 10 Qpeptides (from five Qbricks),

103 interspersed linker peptides, quantification and purification peptides as well as suitable sacrificial sequences at

104 either end, totals approximately 170-220 amino acids, of a size suitable for expression and deployment.

105

106 For more wide-reaching quantification studies, individual short ALACATs are subsequently concatenated in a

107 second reaction. The initial 5-Qbrick constructs are cloned into plasmids that introduce a second set of six

108 overhanging linker sequences, distinct from those used in the 'odd' cycle. These linkers ('even cycle', α, β, γ, δ, ε,

109 λ; Figure 1b) allow assembly of the five short ALACATs into a complete, '*long ALACAT*', capable of encoding

110 Qpeptides for approximately 25 proteins. These QconCATs would be 75-90 kDa (relatively shorter because of the

111 single instances of N-terminal and C-terminal features), typical for cell-free or bacterial expression. Of course, any

112 variant, from two to five short ALACATs, encoding quantification standards for any number of proteins between

113 5 and approximately 30 is possible using this approach. This greatly expands the flexibility of the QconCAT

114 approach. The sequences of the constructs used in this paper, and the cloning syntaxes, are provided in

115 Supplementary Sequence File A.

116

Figure 1| Overall strategy for building block assembly of short and long ALACATs

The smallest unit of an ALACAT is a single double stranded oligonucleotide encoding peptides (one, two, more) for quantification of a single target protein, flanked on either side by tripeptides that preserve the natural primary sequence context. These oligonucleotides include linker regions compatible with a Type IIS restriction enzyme (*Bsa*I) that allows all five Qbricks to be assembled in the correct order in a single ligation reaction (**panel a**, odd cycle assembly) to form short ALACATs. In turn, these short ALACATs contain DNA sequences that are compatible with a second Type IIS restriction enzyme (*Sap*I) and can be similarly assembled in a one tube reaction to create a long ALACAT (**panel b**, even cycle assembly). The vectors for the odd and even cycles both include in frame fusions to glu-fibrinopeptide and c-myc encoding regions (quantification) and a hexahistidine tag (purification).

117

118   As proof of concept, we built an ALACAT from a series of Qbricks encoding standards for 25 human plasma

119   proteins (Supplementary Table 1). We first assembled five short ALACATs and then, in turn, assembled these into

120   a long ALACAT. Each short ALACAT was expressed independently in a wheat germ cell free system (CFS), as well

121   as the long ALACAT and yields of all were high (Figure 2a). Typically, yields were of the order of 500 pmol, which

122   is a substantial quantity for LC-MS/MS based quantification (typically, a single LC-MSMS run would require 50

123   fmol on column). The expressed short and long QconCATs were then digested with trypsin and analysed by LC-

124   MS/MS (Figure 2b). Further information on analysis of the short and long ALACATs is provided in Supplementary

125   Material.

126

Figure 2 | Construction of a human plasma protein QconCAT using the ALACAT strategy

A series of Qbricks were designed, each encoding two peptides for each of 25 plasma proteins. Groups of five were assembled in an odd cycle reaction to short ALACATs (301-305) that were expressed *in vitro* using wheat germ lysate and purified by virtue of their hexahistidine tag. In addition, the short ALACATs were assembled in an even cycle reaction into a single long ALACAT that was also expressed and purified (**panel a**). Each of the ALACATs were then digested and analysed by LC-MSMS; all peptides were detected (**panel c**, infilled peptides are those visible by LC-MS/MS (**panel b**); different colours define the short ALACAT origins of the peptides in the long ALACAT). Using common peptides (glu fibrinopeptide and c-myc epitope) as normalisation controls, the peak areas for peptides in short ALACATs were compared to the areas of the same peptides in the long ALACATs (**panel d**)

127

128 Each QconCAT contained two common peptides - the glu fibrinopeptide (EGVNDNEEGFFSAR) that we have used

129 previously for quantification of the QconCAT [8, 13] and a second peptide derived from the common c-myc

130 peptide (LISEEDLGGR) to give a tag for monitoring expression by western blotting if necessary. We were able to

131 use these two peptides to assess the consistency of the intensity of the quantification peptide, whether in long

132 or short ALACATs (Figure 2c). The correlation was extremely high, confirming that the peptides were cleaved and

133 released similarly, irrespective of the nature of the ALACAT.

134

135 We also demonstrated the synthesis of ALACAT in a *E. coli* cell-free system. The *E. coli* system couples transcription

136 and translation in a single tube, which allows us to skip the *in vitro* transcription reaction required in the wheat

137 cell-free system. In this study, we set up a small-scale reaction system using a microdialysis device (Figure 3). All

138 prepared ALACAT genes were successfully synthesized in this system), and the efficiency of $^{13}C/^{15}N$ incorporation

139 into their lysine and arginine residues was more than 99 %.

140

Figure 3. ALACAT synthesis by *E. coli* cell-free system

Experimental design for cell-free synthesis (**panel a**). Ten small ALACATs (belonging to two series; 'B' and 'H') and one long ALACAT were synthesized in a small-scale cell-free synthesis system using a microdialysis device (panel b). Lysine and arginine residues of the synthesized ALACATs were labelled with $^{13}C/^{15}N$. **Panel b)** Representative SDS-PAGE separation images of the synthesized ALACATs. His-tag purified ALACATs were separated by NuPAGE 4–12 % gradient gels and visualized by CBB staining. Asterisk: ALACAT band. **Panel c)** Selective reaction monitoring (SRM) analysis of ALACAT peptides. The efficiency of stable isotope incorporation was estimated by SRM for two tryptic digested peptides derived from one ALACAT.

Editability of ALACATs

141

142   One of the advantages of the ALACAT approach is the introduction of straightforward editability of the construct.

143   Previously, there was no simple route to exchange one peptide for another without extensive resynthesis of the

144   gene. However, with ALACATs, the editability simplifies the introduction of changes in the sequence and

145   embedded peptides. This editing process can take place at two levels. First, individual peptides can be replaced

146   in Qbricks, and a new short ALACAT could be constructed. The only new DNA required would be the sequence of

147   the Qbrick. Alternatively, an entire short ALACAT could be exchanged, replacing multiple peptides in a single

148   process. This might be of particular value, for example, in a multi-species construct, if some short ALACATs

149   contained species-specific peptide sequences, and others contained sequences that were identical in both

150   species. A simple switch from species A to species B would only require exchange of the relevant short ALACAT in

151   the one-step, even cycle ligation reaction. Further, about 10% of all traditionally synthesised QconCATs failed to

152   express in bacteria [16] and the ability to quickly create a large set of rearrangements of different Qbricks or short

153   ALACATs would be able to deliver a library of ALACATs, with equivalent function, that could be quickly screened

154   for expression potential. Alternatively, this type of combinatorial synthesis could be used to explore adjacency

155   and proximity effects. To test this possibility *in extremis* we therefore initiated a 'one pot' combinatorial ligation

156   of two families of Qbricks, or two families of short ALACATs.

157

158   We tested both levels of editability using the two ALACAT series (B, plasma and H for analysis of the stoichiometry

159   of a metabolic compartment; Supplementary Sequence File A) described above. First, we demonstrated the ease

160   of exchange of short ALACATs by building a combinatorial series of long ALACATs created from random

161   introduction of appropriate short ALACATs – the 'even' cycle. Each position in the long ALACAT could contain a

162   short ALACAT from either the B or H series. Rather than create one editing reaction to prove the swap of one

163   short ALACAT for another, we took a different approach and set up a single reaction, in which we mixed ten short

164   ALACATs derived from the two different families, prefixed B and H, such that B1 and H1 would share common

165   *Sap*I overhang sequences and similarly, the other four pairs (H2/B2 to H5/B5). Thus, short ALACATs H1 and B1

166   would represent a binary choice at position one. In this assembly, a random ligation process would generate 2^5 =

167   32 different combinations, from H1:H2:H3:H4:H5 through, for example, H1:H2:B3:B4:B5 etc. to B1:B2:B3:B4:B5.

168   After the single tube ligation, 81 colonies were picked and the ligation product DNA was sequenced. Of the 32

169   combinations that could have been synthesised, we detected 26 different short ALACATs (80% of all possible

170   different combinations, Figure 4, Supplementary Sequence File B), confirming the ease of editing and

171   reconstruction of new short ALACATs. There was no indication of any systematic bias in the selection of one or

172   the other sets of Qbricks, establishing the ease of random ligation.

**Figure 4| Combinatorial assembly of short ALACATs into long ALACATs**

To test the ease of editability and swapping of short ALACATs into long ALACATs, we created a ligation reaction in which there were two choices of short ALACAT at each of four or five positions (**panel a**). The reaction products were cloned and a total of 81 clones were selected for DNA sequencing, to establish the composition of the long ALACATs (from either the B or H series) were incorporated (**panel b**). There was an even representation of the short ALACATs across the entire structure (**panel c**) and the evenness of the creation of the products is evidenced by the split of the products through the first three positions (**panel d**).

173   To assess the equivalent combinatorial substitution of Qbricks, we performed essentially the same experiment in

174   an 'even' cycle but with two set of Qbricks from the two families (B and H), again picking multiple clones from a

175   single tube ligation reaction. To increase complexity, we created further potential by providing H4 and B5 with

176   two assembly contexts (Figure 5, Supplementary Sequence File C). After assembly, multiple ALACAT clones were

177   picked and sequenced. From this experiment, 26 unique short ALACATs were constructed, spread across 65

178   sequences that were sampled. Of these 65, seven were long variants of five Qbricks (made possible by our

179   construction strategy) but the majority comprised assemblies of four Qbricks, a total of 19 combinations from a

180   set of 24 possibilities were recovered. Further, 16 were unique, two were replicated once, three occurred thrice,

181   two were four-fold, up to one assembly that was sequenced in 16 (approx. 25%) of the clones. It is possible that

182   this bias reflected differences in the relative concentrations of the input DNA sequences, which would allow for

183   the possibility of a degree of tuning of the system to preferred assemblies.

184

Figure 5| Combinatorial assembly of Qbricks into short ALACATs
To test the ease of editability and swapping of Qbricks into short ALACATs, we created a ligation reaction in which there were two choices of Qbrick at each of four or five positions (**panel a**), encoding pairs of quantotypic peptides P_1 and P_2. The reaction products were cloned and a total of 65 clones were selected for DNA sequencing, to establish the composition of the long ALACATs (from either the B or H series) were incorporated (**panel b**). There was a reasonably even representation of the Qbricks across the entire structure (**panel c**).

185

Discussion

The Qbrick concept has multiple advantages over traditional QconCAT gene synthesis and expression. First, the individual Qbrick DNA oligonucleotides can be drawn from an ever-expanding library, stored at the point of synthesis, and thus, the clustering of Qpeptides into QconCATs becomes a late decision, driven by the interests of specific users and programmes. Secondly, ALACATs can be designed and delivered at any size, according to the focus and depth of individual quantitative proteomics studies. For example, two or three short ALACATs can be combined to form highly efficient QconCATs of intermediate size. Lastly, if specific peptides are suboptimal for a particular mass spectrometric approach, often an unknown factor before the construct is made, it is trivial to replace one Qbrick, build a new short ALACAT, and if required, subsequently assemble the new short ALACAT into the full length ALACAT, both steps being single-tube reactions. This is an exciting improvement in QconCAT deployment, providing an efficiency and flexibility which, coupled with cell-free synthesis and MEERCAT, means that large scale absolute proteome quantifications are now eminently feasible, sustainable and modifiable. Moreover, many stages of the ALACAT workflow are suitable for delivery through laboratory automation, reducing the need for human intervention. The Qbrick approach means that it would be possible to create an ever-expanding resource of Qbrick DNA (in the form of double stranded oligonucleotides) that could be assembled 'to order' in response to requests by any research group. There would be no reliance on prior clustering of peptides, and the assembly would be a trivial additional step. Moreover, the ability to 'swap out' specific Qbricks without having to redesign and build the QconCAT from scratch means that problematic peptides will be rapidly expunged from the resource (Figure 6). The advantages of having 'editable QconCATs' cannot be overstated. This added flexibility in standard design and optimisation, coupled with ever increasing selectivity and sensitivity of LC-MS/MS platforms, makes absolute quantification of part, or even all, of a proteome increasingly feasible.

Lastly, QconCATs, assemblies of peptides generated by proteolysis, are a simple route to the generation of stoichiometric quantities of a set of peptides that can be used for purposes other than absolute quantification, such as instrument quality control or calibration of retention time index ([19–23]).The combinatorial experiments described in this paper, for example, create the ability to build a large number of different combinations of peptides from a common library, and could be used in the understanding of local influences on ionisation, or even to test the emergent methods for prediction of precursor or product ion intensity [24–29]. The more straightforward the production methodology, the more likely tests of such predictive methods can be created.

Figure 6| A model for the creation of an ALACAT resource

From a library of Qbricks (that may include redundant sequences to increase the choice of quantotypic peptides for specific proteins) assembly into short ALACATs would provide a test system to assess the suitability of peptides for quantification. Once the short ALACATs are optimised, sets of them could subsequently be assembled into long ALACATs. Long ALACAT DNA can be readily used to drive protein synthesis in the end user laboratory, labelled as appropriate.

215

216

ALACATs: à la carte QconCATs

Acknowledgments

223 **EXPERIMENTAL**

224 **Materials and reagents.** All enzymes, competent cells and manual DNA purification kits were purchased from

225 New England Biolabs (Hitchin, UK), all oligonucleotides were purchased desalted and lyophilised from

226 Integrated DNA Technologies BVBA (Leuven, Belgium) or Eurofins Genomics (Ebersberg, Germany). All

227 bacterial media and antibiotics were purchased from Formedium Ltd (Hunstanton, UK).

228

229 **Production of pOdd and pEven acceptor vectors.** Plasmid pEU01-MCS (CellFree Sciences, Ehime, Japan) was

230 domesticated via site-directed mutagenesis to remove unwanted *Bsa*I and *Sap*I restriction sites. pOdd

231 vectors were produced by inserting a lacZ cassette with *Sap*I and *Bsa*I sites as indicated with appropriate

232 syntaxes flanked N-terminally by GluFib and Myc tag linkers and C-terminally with 6x His-Tag and stop

233 codons. pEven vectors were produced similarly but the Amp^R gene was exchanged for $Spec^R$ gene amplified

234 from pGM134_1 and cloned via an NEBuilder (NEB, UK) reaction. All lacZ cassettes were synthesised by Twist

235 Bioscience (San Francisco, USA) and cloned as single fragments into modified pEU01-MCS via NEBuilder,

236 producing pOdd vectors pGM247_2 − 6 and pEven vectors pGM247_8 − 12.

237

238 **Design of oligonucleotides and production of QBrick DNA Blocks.** QBrick peptide sequences were reverse

239 translated using Geneious software (Biomatters Ltd), set up to use the *Escherichia coli* K12 codon usage table

240 [30] and to avoid internal restriction sites of *Bsa*I, *Sap*I, *Bbs*I and *Bsm*BI and >5 nt homopolymers. These were

241 converted to overlapping oligonucleotides (T_{ann} approx. 60°C). Required 5' overhangs for *Bsa*I or *Sap*I

242 recognition sequences and molecular syntaxes were then added. Pairs of overlapping oligonucleotides were

243 mixed at 2.5 μM ea. (final conc.) in Q5 2x mastermix in 20 μl total reaction. These were annealed and

244 extended using the following thermocycler parameters: 98°C for 60 s followed by five cycles of 98°C for 10

245 s, 60°C for 30 s, 72°C for 15 s and a final incubation at 72°C for 60 s. These reactions were diluted 1:100 in

246 water before added to cloning reactions below (approx. 25 fmol/μl).

247

248 **Odd level cloning reactions (Short ALACATs).** Required QBrick blocks (~25 fmol·μL^{-1}) were reacted with empty

249 pOdd vector in 10 μL total as follows: 0.5 μL each QBrick block, 10 ng pOdd vector, 1 μL T4 DNA Ligase Buffer,

250 0.5 μL T4 DNA Ligase (400 U·μL^{-1}), 0.5 μL *Bsa*I (10 U·μL^{-1}). These were incubated with the following conditions:

251 37°C for 10 min, followed by 50 cycles of 37°C for 1 min and 16°C for 1.5 min before final 50°C for 5 min. 1

252 μL of the reaction was transformed into 25 μL of NEB 5-alpha chemically competent cells. 20% were plated

253 onto LB agar plates containing 100 μg·mL^{-1} Carbenicillin, 20 μg·mL^{-1} X-Gal and 100 μM IPTG for blue/white

254 selection. White colonies were then screened by colony PCR using universal screening primers (Forward: 5'-

255 TAACCACCTATCTACATCACC-3' and Reverse: 5'-CGAGCTCGAGAACTAGTGAT-3'). PCR products were analysed

256 using QIAxcel DNA Screening Gel automated electrophoresis (QIAGEN, Manchester, UK). Correct PCR

257 products were cleaned with ExoCIP and Sanger sequenced (Source Bioscience Ltd, Nottingham, UK) to
258 confirm the sequence.

259

260 **Even level cloning reactions (Long ALACATs).** Required pOdd clones (10 ng·µL^{-1}) were reacted with empty
261 pEven vector in 10 µL total as follows: 0.5 µL each pOdd clone, 10 ng pEven vector, 1 µL 10x T4 Ligase Buffer,
262 0.5 µL T4 DNA Ligase (400 U·µL^{-1}), 0.5 µL *Sap*I (10 U·µL^{-1}). These were incubated at 37°C for 120 min. 1 µL of
263 the reaction was transformed into 25 µL of NEB 5-alpha chemically competent cells. 20% were plated onto
264 LB agar plates containing 50 µg·mL^{-1} Spectinomycin, 20 µg·mL^{-1} X-Gal and 100 µM IPTG. White colonies were
265 then screened by colony PCR using universal screening primers (Forward: 5'-TAACCACCTATCTACATCACC-3'
266 and Reverse: 5'-CGAGCTCGAGAACTAGTGAT-3'). PCR products were analysed using QIAxcel DNA Screening
267 Gel electrophoresis.

268

269 **Cell-free expression of short and long ALACATs.** For each ALACAT, 2 µg DNA in pEU-E01 vector (CellFree
270 Sciences Co., Ltd, Japan) was used for a single expression reaction. Synthesis was completed in 240 µL scale
271 using WEPR8240H full Expression kit (2BScientific Ltd, UK). A positive control (pEU-E01-DHFR coding
272 dihydrofolate reductase gene derived from *E. coli*) and negative control (pEU-E01-MCS empty vector) were
273 used, both supplied with the kit. Full kit instructions were followed, including preparation of WEPRO8240H
274 aliquots and 2 x SUB AMIX reagent. The Transcription Mix for each expression was prepared with 20 U RNase
275 inhibitor, 20 U SP6 RNA Polymerase, 50 nmol NTP mix and a 0.2 x dilution Transcription Buffer. DNA for the
276 ALACAT or controls, and nuclease-free water, were added to a final volume of 20 µL. The transcription
277 reaction occurred over six hours at 37 °C and the resulting mRNA was stored briefly at room temperature
278 before transcription.

279

280 A 1 x SUB AMIX was prepared with a 0.5 x dilution of 2 x SUB AMIX into nuclease-free water and 60 nmol of
281 each of the standard 20 amino acids (R, K, A, N, D, C, E, Q, G, H, I, L, M, F, P, S, T, W, Y, V), with substituted
282 stable isotope labelled [^{13}C$_6$],[^{15}N$_4$] arginine and [^{13}C$_6$],[^{15}N$_2$] lysine (CK Isotopes Ltd, UK). The Translation Mix
283 for each expression was prepared with 12 nmol of each of the same standard 20 amino acids, including ^{13}C$_6$
284 ^{15}N Arg and Lys, combined with 0.8 µg creatinine kinase, 10 µL WEPRO8240H wheat germ lysate, 0.5 x
285 dilution of 2 x SUB AMIX, and 10 µL of mRNA for each ALACAT or standard. A 96-well plate was prepared with
286 200 µL of 1 x SUB AMIX in each well. The Translation Mixture was carefully pipetted beneath the SUB AMIX
287 in each well to form a bilayer. The plate was sealed and incubated at 16 °C for 16 hours.

288

289 *E. coli* cell-free synthesis was performed using a Musaibou-Kun protein synthesis kit (Catalog #A183-0242,
290 Taiyo Nippon Sanso Corporation, Tokyo, Japan). For ALACAT synthesis, an amino acid cocktail with lysine and

ALACATs: à la carte QconCATs

291 arginine universally labeled with ^{13}C and ^{15}N (Catalog # A91-0128, Taiyo Nippon Sanso Corporation) was used.

292 All synthetic reactions were performed using an Xpress micro-dialyzer MD100 with molecular weight cut-off

293 of 12–14 kDa (Scienova, Spitzweidenweg, Germany) inserted into a 2 mL microtube. Before synthesis, 825

294 µL of the outer solution was mixed with 75 µL amino acid cocktail and 100 µL distilled water, incubated at 30

295 °C, and added to the outside of the dialysis unit at the start of synthesis. Then, 77.5 µL of the internal solution

296 for synthesis was mixed with 10 µL template DNA (50 ng/µL), 7.5 µL amino acid cocktail, and 5 µL distilled

297 water, and added to the dialysis unit. The synthesis reaction was carried out at 30 °C for 18 hours. After the

298 synthesis was completed, all the solution in the dialysis unit was collected into a new tube.

299

300 **ALACAT purification.** Note that the positive control used for expression does not have a hexa-histidine tag

301 and therefore both controls were used as negative controls in this next stage of the protocol. The 240 µL

302 contents of each individual well of the 96 well plate was transferred to a low binding tube (Biotix Inc., US).

303 This was then combined with 400 µL Bind Buffer pH 7.4 (20 mM sodium phosphate, 0.5 M sodium chloride,

304 20 mM imidazole, 6 M guanidine hydrochloride), and incubated at room temperature for one hour using a

305 rotor mixer, before addition of 10 µL Ni Sepharose suspension (GE Healthcare Ltd, UK) and a further one

306 hour incubation. Centrifuge filters (Corning Costar Spin-X 0.45 um pore size cellulose acetate membrane,

307 Merck, UK) were washed once with 750 µL Bind Buffer and centrifuged, before addition of the sample and

308 Ni Sepharose, and further centrifugation; all centrifuge steps used 6,000 x g 2 minutes 4 °C. This was followed

309 by three further washes by centrifugation with Bind Buffer; two 400 µL washes and one 200 µL wash. Sample

310 was eluted by centrifugation from the resin with two additions of 15 µL Elution Buffer pH 7.4 (20 mM sodium

311 phosphate, 0.5 M sodium chloride, 1 M imidazole, 6 M guanidine hydrochloride), after each addition the

312 resin and buffer were agitated to mix before centrifugation.

313

314 The final 30 µL elution was transferred to a low binding tube for protein precipitation. To each tube 600 µL

315 HPLC grade methanol (Fisher Scientific Ltd, UK) was added and mixed well before addition of 150 µL

316 chloroform and 400 µL HPLC grade water (VWR International, UK) to precipitate proteins. Following

317 centrifugation at 13,000 x g for 3 minutes a bilayer was formed, the uppermost layer of which was carefully

318 removed. A further 600 µL methanol was added and gently mixed by inversion. After a second centrifugation

319 step the majority of the liquid was removed and discarded, with the remaining liquid allowed to evaporate.

320 The precipitate was resuspended in 30 µL 25 mM ammonium bicarbonate, with 0.1 % (w/v) RapiGest^{TM} SF

321 surfactant (Waters, UK) and protease inhibitors (Roche cOmplete^{TM}, Mini, EDTA-free Protease Inhibitor

322 Cocktail, Merck, UK). Before tryptic digestions the protein concentration of each sample was determined

323 using a NanoDrop Spectrophotometer (ThermoFisher Scientific, UK).

324

325 **Tryptic digestion.** For digestion, 0.5 µg protein for each was treated with 0.05 % (w/v) RapiGest™ SF

326 surfactant at 80 °C for 10 minutes, reduced with 4 mM dithiothreitol (Melford Laboratories Ltd., UK) at 60 °C

327 for 10 minutes and subsequently alkylated with 14 mM iodoacetamide at room temperature for 30 minutes.

328 Proteins were digested with 0.01 µg Trypsin Gold, Mass Spectrometry Grade (Promega, US) at 37 °C

329 overnight. Digests were acidified by addition of trifluoroacetic acid (Greyhound Chromatography and Allied

330 Chemicals, UK) to a final concentration of 0.5 % (v/v) and incubated at 37 °C for 45 minutes before

331 centrifugation at 13,000 x g 4°C to remove insoluble non-peptidic material.

332

333 **LC-MS/MS.** Samples were analysed using an UltiMate™ 3000 RSLCnano system coupled to a Q Exactive™ HF

334 Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (ThermoFisher Scientific, UK). Protein digests were loaded

335 onto a trapping column (Acclaim PepMap 100 C18, 75 µm x 2 cm, 3 µm packing material, 100 Å) using 0.1 %

336 (v/v) trifluoroacetic acid, 2 % (v/v) acetonitrile in water at a flow rate of 12 µL min-1 for 7 min. For samples

337 301, 302 and 304, 5 ng was loaded, and for the Long ALACAT, 303 and 305, 10ng was loaded. The peptides

338 were eluted onto the analytical column (EASY-Spray PepMap RSLC C18, 75 µm x 50 cm, 2 µm packing

339 material, 100 Å) at 30 °C using a linear gradient of 30 minutes rising from 3 % (v/v) acetonitrile/0.1 % (v/v)

340 formic acid (Fisher Scientific, UK) to 40 % (v/v) acetonitrile/0.1 % (v/v) formic acid at a flow rate of 300 nL

341 min^{-1}. The column was then washed with 79 % (v/v) acetonitrile/0.1 % (v/v) formic acid for 5 min, and re-

342 equilibrated to starting conditions. The nano-liquid chromatograph was operated under the control of Dionex

343 Chromatography MS Link 2.14.

344

345 The nano-electrospray ionisation source was operated in positive polarity under the control of QExactive HF

346 Tune (version 2.5.0.2042), with a spray voltage of 1.8 kV and a capillary temperature of 250 °C. The mass

347 spectrometer was operated in data-dependent acquisition mode. Full MS survey scans between m/z 350-

348 2000 were acquired at a mass resolution of 60,000 (full width at half maximum at m/z 200). For MS, the

349 automatic gain control target was set to $3e^6$, and the maximum injection time was 100 ms. The 16 most

350 intense precursor ions with charge states of 2-5 were selected for MS/MS with an isolation window of 2 m/z

351 units. Product ion spectra were recorded between m/z 200-2000 at a mass resolution of 30,000 (full width

352 at half maximum at m/z 200). For MS/MS, the automatic gain control target was set to $1e^5$, and the maximum

353 injection time was 45 ms. Higher-energy collisional dissociation was performed to fragment the selected

354 precursor ions using a normalised collision energy of 30 %. Dynamic exclusion was set to 30 s.

355

356 The raw MS data files were loaded into Thermo Proteome Discoverer v.1.4 (ThermoFisher Scientific, UK) and

357 searched against a custom ALACATs database using Mascot v.2.7 (Matrix Science London, UK) with trypsin

358 as the specified enzyme, one missed cleavage allowed, carbamidomethylation of cysteine, label

ALACATs: à la carte QconCATs

359 $[^{13}C_6][^{15}N_2]$lysine and $[^{13}C_6][^{15}N_4]$arginine set as fixed modifications and oxidation of methionine set as a

360 variable modification. A precursor mass tolerance of 10 ppm and a fragment ion mass tolerance of 0.01 Da

361 were applied.

362

363 **REFERENCES**

364 1. Gerber, S. A.; Rush, J.; Stemman, O.; Kirschner, M. W., Gygi, S. P.: Absolute quantification of proteins and
365 phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A 2003, 100:6940-6945, doi:
366 10.1073/pnas.0832254100
367 2. Kirkpatrick, D. S.; Gerber, S. A., Gygi, S. P.: The absolute quantification strategy: a general procedure for
368 the quantification of proteins and post-translational modifications. Methods 2005, 35:265-273, doi:
369 10.1016/j.ymeth.2004.08.018
370 3. Dupuis, A.; Hennekinne, J. A.; Garin, J., Brun, V.: Protein Standard Absolute Quantification (PSAQ) for
371 improved investigation of staphylococcal food poisoning outbreaks. Proteomics 2008, 8:4633-4636, doi:
372 10.1002/pmic.200800326
373 4. Brun, V.; Masselon, C.; Garin, J., Dupuis, A.: Isotope dilution strategies for absolute quantitative
374 proteomics. J Proteomics 2009, 72:740-749, doi: 10.1016/j.jprot.2009.03.007
375 5. Picard, G.; Lebert, D.; Louwagie, M.; Adrait, A.; Huillet, C.; Vandenesch, F.; Bruley, C.; Garin, J.; Jaquinod,
376 M., Brun, V.: PSAQ™ standards for accurate MS-based quantification of proteins: from the concept to
377 biomedical applications. J Mass Spectrom 2012, 47:1353-1363, doi: 10.1002/jms.3106
378 6. Persson, A.; Hober, S., Uhlén, M.: A human protein atlas based on antibody proteomics. Curr Opin Mol
379 Ther 2006, 8:185-190, doi:
380 7. Zeiler, M.; Straube, W. L.; Lundberg, E.; Uhlen, M., Mann, M.: A Protein Epitope Signature Tag (PrEST)
381 library allows SILAC-based absolute quantification and multiplexed determination of protein copy
382 numbers in cell lines. Mol Cell Proteomics 2012, 11:O111.009613, doi: 10.1074/mcp.O111.009613
383 8. Brownridge, P.; Holman, S. W.; Gaskell, S. J.; Grant, C. M.; Harman, V. M.; Hubbard, S. J.; Lanthaler, K.;
384 Lawless, C.; O'Cualain, R.; Sims, P.; Watkins, R., Beynon, R. J.: Global absolute quantification of a
385 proteome: Challenges in the deployment of a QconCAT strategy. Proteomics 2011, 11:2957-2970, doi:
386 10.1002/pmic.201100039
387 9. Simpson, D. M., Beynon, R. J.: QconCATs: design and expression of concatenated protein standards for
388 multiplexed protein quantification. Anal Bioanal Chem 2012, 404:977-989, doi: 10.1007/s00216-012-
389 6230-1
390 10. Beynon, R. J.; Doherty, M. K.; Pratt, J. M., Gaskell, S. J.: Multiplexed absolute quantification in proteomics
391 using artificial QCAT proteins of concatenated signature peptides. Nat Methods 2005, 2:587-589, doi:
392 10.1038/nmeth774
393 11. Pratt, J. M.; Simpson, D. M.; Doherty, M. K.; Rivers, J.; Gaskell, S. J., Beynon, R. J.: Multiplexed absolute
394 quantification for proteomics using concatenated signature peptides encoded by QconCAT genes. Nat
395 Protoc 2006, 1:1029-1043, doi: 10.1038/nprot.2006.129
396 12. Rivers, J.; Simpson, D. M.; Robertson, D. H.; Gaskell, S. J., Beynon, R. J.: Absolute multiplexed quantitative
397 analysis of protein expression during muscle development using QconCAT. Mol Cell Proteomics 2007,
398 6:1416-1427, doi: 10.1074/mcp.M600456-MCP200
399 13. Lawless, C.; Holman, S. W.; Brownridge, P.; Lanthaler, K.; Harman, V. M.; Watkins, R.; Hammond, D. E.;
400 Miller, R. L.; Sims, P. F.; Grant, C. M.; Eyers, C. E.; Beynon, R. J., Hubbard, S. J.: Direct and Absolute
401 Quantification of over 1800 Yeast Proteins via Selected Reaction Monitoring. Mol Cell Proteomics 2016,
402 15:1309-1322, doi: 10.1074/mcp.M115.054288
403 14. Yang, M.; Simpson, D. M.; Wenner, N.; Brownridge, P.; Harman, V. M.; Hinton, J. C. D.; Beynon, R. J., Liu, L.
404 N.: Decoding the stoichiometric composition and organisation of bacterial metabolosomes. Nat Commun
405 2020, 11:1976, doi: 10.1038/s41467-020-15888-4
406 15. Takemori, N.; Takemori, A.; Matsuoka, K.; Morishita, R.; Matsushita, N.; Aoshima, M.; Takeda, H.;
407 Sawasaki, T.; Endo, Y., Higashiyama, S.: High-throughput synthesis of stable isotope-labeled

ALACATs: à la carte QconCATs   19

408 transmembrane proteins for targeted transmembrane proteomics using a wheat germ cell-free protein
409 synthesis system. Mol Biosyst 2015, 11:361-365, doi: 10.1039/c4mb00556b

410 16. Takemori, N.; Takemori, A.; Tanaka, Y.; Endo, Y.; Hurst, J. L.; Gómez-Baena, G.; Harman, V. M., Beynon, R.
411 J.: MEERCAT: Multiplexed Efficient Cell Free Expression of Recombinant QconCATs For Large Scale
412 Absolute Proteome Quantification. Mol Cell Proteomics 2017, 16:2169-2183, doi:
413 10.1074/mcp.RA117.000284

414 17. Shetty, R. P.; Endy, D., Knight, T. F.: Engineering BioBrick vectors from BioBrick parts. J Biol Eng 2008, 2:5,
415 doi: 10.1186/1754-1611-2-5

416 18. Pollak, B.; Cerda, A.; Delmans, M.; Álamos, S.; Moyano, T.; West, A.; Gutiérrez, R. A.; Patron, N. J.; Federici,
417 F., Haseloff, J.: Loop assembly: a simple and open system for recursive fabrication of DNA circuits. New
418 Phytol 2019, 222:628-640, doi: 10.1111/nph.15625

419 19. Eyers, C. E.; Simpson, D. M.; Wong, S. C.; Beynon, R. J., Gaskell, S. J.: QCAL--a novel standard for assessing
420 instrument conditions for proteome analysis. J Am Soc Mass Spectrom 2008, 19:1275-1280, doi:
421 10.1016/j.jasms.2008.05.019

422 20. Shinoda, K.; Tomita, M., Ishihama, Y.: Aligning LC peaks by converting gradient retention times to
423 retention index of peptides in proteomic experiments. Bioinformatics 2008, 24:1590-1595, doi:
424 10.1093/bioinformatics/btn240

425 21. Moruz, L.; Tomazela, D., Käll, L.: Training, selection, and robust calibration of retention time models for
426 targeted proteomics. J Proteome Res 2010, 9:5209-5216, doi: 10.1021/pr1005058

427 22. Holman, S. W.; McLean, L., Eyers, C. E.: RePLiCal: A QconCAT Protein for Retention Time Standardization in
428 Proteomics Studies. J Proteome Res 2016, 15:1090-1102, doi: 10.1021/acs.jproteome.5b00988

429 23. Zolg, D. P.; Wilhelm, M.; Yu, P.; Knaute, T.; Zerweck, J.; Wenschuh, H.; Reimer, U.; Schnatbaum, K., Kuster,
430 B.: PROCAL: A Set of 40 Peptide Standards for Retention Time Indexing, Column Performance Monitoring,
431 and Collision Energy Calibration. Proteomics 2017, 17doi: 10.1002/pmic.201700263

432 24. Frank, A. M.: Predicting intensity ranks of peptide fragment ions. J Proteome Res 2009, 8:2226-2240, doi:
433 10.1021/pr800677f

434 25. Eyers, C. E.; Lawless, C.; Wedge, D. C.; Lau, K. W.; Gaskell, S. J., Hubbard, S. J.: CONSeQuence: prediction of
435 reference peptides for absolute quantitative proteomics using consensus machine learning approaches.
436 Mol Cell Proteomics 2011, 10:M110.003384, doi: 10.1074/mcp.M110.003384

437 26. Sun, S.; Yang, F.; Yang, Q.; Zhang, H.; Wang, Y.; Bu, D., Ma, B.: MS-Simulator: predicting y-ion intensities
438 for peptides with two charges based on the intensity ratio of neighboring ions. J Proteome Res 2012,
439 11:4509-4516, doi: 10.1021/pr300235v

440 27. Jarnuczak, A. F.; Lee, D. C.; Lawless, C.; Holman, S. W.; Eyers, C. E., Hubbard, S. J.: Analysis of Intrinsic
441 Peptide Detectability via Integrated Label-Free and SRM-Based Absolute Quantitative Proteomics. J
442 Proteome Res 2016, 15:2945-2959, doi: 10.1021/acs.jproteome.6b00048

443 28. Wichmann, C.; Meier, F.; Virreira Winter, S.; Brunner, A. D.; Cox, J., Mann, M.: MaxQuant.Live Enables
444 Global Targeting of More Than 25,000 Peptides. Mol Cell Proteomics 2019, 18:982-994, doi:
445 10.1074/mcp.TIR118.001131

446 29. Gessulat, S.; Schmidt, T.; Zolg, D. P.; Samaras, P.; Schnatbaum, K.; Zerweck, J.; Knaute, T.; Rechenberger,
447 J.; Delanghe, B.; Huhmer, A.; Reimer, U.; Ehrlich, H. C.; Aiche, S.; Kuster, B., Wilhelm, M.: Prosit: proteome-
448 wide prediction of peptide tandem mass spectra by deep learning. Nat Methods 2019, 16:509-518, doi:
449 10.1038/s41592-019-0426-7

450 30. Nakamura, Y.; Gojobori, T., Ikemura, T.: Codon usage tabulated from international DNA sequence
451 databases: status for the year 2000. Nucleic Acids Res 2000, 28:292, doi: 10.1093/nar/28.1.292

452